Livanova PLC has announced the launch and enrollment of the first patient for its observational post-market study to assess the effectiveness of its Vagus Nerve Stimulation Therapy. The study will assess the short, medium and long term impact of ‘VNS Therapy’ on those suffering from treatment resistant depression. Read the article here.
Subscribe to LWD
Join 1,826 other subscribers